106. Immunotherapy. 2018 Feb 1;10(4):255-263. doi: 10.2217/imt-2017-0080.Standing in the GAP : To formulate a novel radioimmunotherapy regime to improvethe long-term outcome in breast cancer.Pock HL(1)(2), Wei Bryan TY(3), Hoon TP(4), Iqbal J(5), Ching LY(2), Tee GY(2),Wai TK(3), Chong TH(6), Wee OK(7), Wei YK(8).Author information: (1)Department of Clinical Pathology, Singapore General Hospital, Singapore.(2)Department of Hematology, Singapore General Hospital, Singapore.(3)Department of Clinical Research, Singapore General Hospital, Singapore.(4)Division of Pathology, Singapore General Hospital, Singapore.(5)Department of Anatomical Pathology, Singapore General Hospital, Singapore.(6)Department of Medical Oncology, National Cancer Center Singapore, Singapore.(7)Department of Surgical Oncology, National Cancer Center Singapore, Singapore.(8)Department of Radiation Oncology, National Cancer Center Singapore, Singapore.AIM: The new radioimmunotherapeutic regime GAP15R aims to stimulateglucocorticoid-induced TNF-related protein (G) to overcome Treg suppression; add IFN-Î± (A) to promote inflammatory milieu; block PD1 (P) to disinhibit T effector cytotoxicity; add IL-15 (15) to enhance danger signals & T-cell expansion; andapply radiation (R) at critical time point to sustain localized inflammation.Patients & methods/materials & methods: This was tested in a murine 4T1metastatic breast carcinoma model given GAP15R with regular monitoring of tumorvolume and complications.RESULTS: We had demonstrated long-term complete remission up to 50% of treatedmice, which is not associated with major treatment-related complication, in caseswith specific tumor burden.CONCLUSION: GAP15R is efficacious with potential to be applicable to othertumors.DOI: 10.2217/imt-2017-0080 PMID: 29421981 